Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED
Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cerevel Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Tuesday Talk: Big-Tech Under Attack ↗
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
News headline image
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? ↗
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. 
Via Benzinga
News headline image
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 ↗
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
Via InvestorPlace
News headline image
Is AbbVie Stock a Buy Now? ↗
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. 
Via The Motley Fool
News headline image
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
News headline image
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
News headline image
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall ↗
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. 
Via Benzinga
News headline image
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures ↗
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
ABBV: This Top Biotech Just Went On A Buying Spree ↗
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
News headline image
7 Dividend Aristocrats That Will Pay You for Years to Come ↗
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. 
Via InvestorPlace
News headline image
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
News headline image
Is AbbVie Stock a Buy Now? ↗
The company is grappling with losing Humira's patent protection in 2023. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
The 7 Most Undervalued Growth Stocks to Buy in December ↗
Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. 
Via InvestorPlace
News headline image
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
The 3 Best Cheap Stocks to Buy in December ↗
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. 
Via InvestorPlace
News headline image
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December ↗
These companies offer above-average income streams that should continue rising. 
Via The Motley Fool
News headline image
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? ↗
The big drugmaker went on a holiday shopping spree. 
Via The Motley Fool
News headline image
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? ↗
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days. 
Via The Motley Fool
News headline image
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals ↗
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.